I believe the market will finally pay respect to pay respect to Mesoblast. I see them making up significant ground on Pluristem and Athersys and overtaking both in the coming days.
Mesoblast is only up 28% since Jan 2020. Athersys is up 76% and Pluristem up 162% over the same period.
IMHO Mesoblast is ahead of both in the race for a therapy to treat ARDS and COVID patients.
Considering their pipeline and what the have install over the next few weeks and months and with other stocks dropping like flys, I see Mesoblast attracting significant attention in this subdued period on the back of real prospects for GVHD, ARDS and CHF.
MSB 2020 charts, page-89
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.5¢ |
Change
-0.025(2.58%) |
Mkt cap ! $1.078B | |||
| Open | High | Low | Value | Volume |
| 98.0¢ | 98.5¢ | 94.0¢ | $2.482M | 2.602M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 71720 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 10463 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |